Ascletis, Inc.

76 articles about Ascletis, Inc.

• Goldman, Sachs & Co. Invests US$20 Million In Ascletis, Inc.

  12/2/2015

• Ascletis, Inc. Scores $35 Million Financing

  9/2/2015

• Ascletis, Inc. Phase II Clinical Trial Of Its Interferon-Free HCV Regimen In Taiwan

  8/31/2015

• Ascletis, Inc. As The First Chinese Company To File Clinical Applications For Interferon-Free HCV Treatment

  6/24/2015

• Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug

  3/18/2015

• Ascletis, Inc. Gains China Market Rights From Janssen Research & Development to a Clinical Stage HIV Protease Inhibitor

  4/30/2013

• Week in Review: Ascletis, Inc. Collaborates With Roche on HCV Treatment

  4/22/2013

• Roche, Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China

  4/15/2013

• ChinaBio(R) LLC Week in Review: Ascletis, Inc. In-Licenses China Rights to RNAi Cancer Drug

  7/16/2012

• Alnylam Pharmaceuticals, Ascletis, Inc. Create Strategic Collaboration to Develop ALN-VSP

  7/12/2012

• US-China Pharmaceutical Venture Ascletis, Inc. Receives Record-Level Research and Development Grant from Hangzhou

  1/4/2012

• Ascletis, Inc. Named for Financing Deal of the Year

  12/1/2011

• Ascletis, Inc. Adds Support to $100 Million in Startup Capital

  7/21/2011

• Ascletis, Inc. Announces New Support from Hangzhou, China and The Hamner Institutes for Health Sciences in Research Triangle Park, NC

  7/20/2011

• Ascletis, Inc. Names Allan Baxter, PhD, Former GlaxoSmithKline Global Head of Medicines Development, as Chief Strategy Officer

  7/11/2011

• US-China Based Ascletis, Inc. Raises $100 Million from Private Chinese Investors for Specialty Therapeutics Venture

  4/6/2011